HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 11, 1998, Pages 1671-1678

  Bellosta, S ^a   Via, D ^c   Canavesi, M ^a   Pfister, P ^d   Fumagalli, R ^a   Paoletti, R ^a   Bernini, F ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Macrophages; Metalloproteinases; Plaque stability; Statins

Indexed keywords

FLUINDOSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ANIMAL EXPERIMENT; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CHOLESTEROL SYNTHESIS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; IMMUNOBLOTTING; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0031775709     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.11.1671     Document Type: Article

References (16)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond). 1993;362:801-809.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
3. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
4. Fernandez-Ortiz A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. Am J Coll Cardiol. 1994;23:1562-1569.
5. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD. Collagen types I and II, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: snap-wise variations. Atherosclerosis. 1992;96:71-81.
6. Wight TN. The extracellular matrix and atherosclerosis. Curr Opin Lipidol. 1995;6:326-334.
7. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
8. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125-2131.
9. Newman KM, Ogata Y, Malon AM, Irizzary E, Gandhi RH, Nagase H, Tilson MD. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aneurysm. Arterioscler Thromb. 1994;14:1315-1320.
10. James TW, Wagner R, White LA, Zwolak RM, Brinkerhoff CE. Induction of collagenase and stromelysin gene expression by mechanical injury in vascular smooth muscle-derived cell line. J Cell Physiol. 1993;157:426-437.
11. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
12. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
13. More R, Underwood M, Brack MJ, de Bono D, Gershlick AK. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc Res. 1995;29:22-26.
14. Southgate KM, Banning AP, Groves PH, Cheadle H, Newby AC. Upregulation of basement membrane-degrading metalloproteinases by balloon angioplasty in pigs. Br Heart J. 1994;71(suppl 5):65. Abstract.
15. Birkedal-Hansen H, Moore W, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
16. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.